Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Radiation Injuries 1Prostatic Neoplasms 1Neoplasms, Second Primary 1Lung Neoplasms 1Head and Neck Neoplasms 1Eye Diseases 1Colorectal Neoplasms 1Cognitive Dysfunction 1Cardiovascular Diseases 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × beta Carotene × Clear all
NCT00169845 2018-03-14

Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients

Laval University

Phase 3 Completed
540 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Radiation Injuries, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡